Natera Completes Enrollment for RenaCARE Study
10:50AM ET 8/11/2022 MT NewswiresNatera (NTRA) said Thursday it has completed the enrollment for the RenaCARE study to evaluate the utility of its Renasight genetic testing panel....
Quotes Snapshot > NTRA
Natera Inc NTRA:NASDAQ
Last Price$55.17NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change0(0.00%)
Bid (Size)$55.16 (85)
Ask (Size)$57.00 (2)
Day Low / HighN/A - N/A
Volume1.3 M
Read more news Recent News
Sector Update: Health Care Stocks Mixed Premarket Thursday
9:13AM ET 8/11/2022 MT NewswiresHealth care stocks were mixed premarket Thursday. The Health Care SPDR (XLV) was down 0.44% and the iShares NASDAQ Biotechnology Index (IBB) was advancing...
Natera Files Pre-Submission With FDA for Prenatal Test
7:15AM ET 8/11/2022 MT NewswiresNatera (NTRA) said late Wednesday it filed a pre-submission with the US Food and Drug Administration for its Panorama prenatal test. The pre-submission...
--JPMorgan Adjusts Natera's Price Target to $100 from $80, Keeps Overweight Rating
8:03AM ET 8/05/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2022 Results - Earnings Call Transcript
6:40PM ET 8/06/2022 Seeking AlphaNatera, Inc. 2022 Q2 - Results - Earnings Call Presentation
5:44PM ET 8/05/2022 Seeking AlphaLantheus Holdings Rules The Medical Diagnostics Business World
3:28PM ET 7/06/2022 Seeking AlphaNothing Compelling About Natera
11:25AM ET 6/24/2022 Seeking AlphaCompany Profile
Business DescriptionNatera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX. View company web site for more details
| Address | 13011 McCallen Pass Austin, Texas 78753 |
| Phone | +1.650.249.9090 |
| Number of Employees | 975 |
| Recent SEC Filing | 08/05/2022 10-Q |
| President, Chief Executive Officer & Director | Stephen Chapman |
| Chief Operating Officer | Robert A. Schueren |
| Chief Financial Officer | Michael Burkes Brophy |
| Chief Scientific Officer | Eric A. Evans |
Company Highlights
| Price Open | $54.21 |
| Previous Close | $53.59 |
| 52 Week Range | $26.10 - 129.09 |
| Market Capitalization | $5.3 B |
| Shares Outstanding | 97.0 M |
| Sector | Health Services |
| Industry | Medical/Nursing Services | Next Earnings Announcement | 11/03/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$6.07 |
| Beta vs. S&P 500 | N/A |
| Revenue | $257.7 M |
| Net Profit Margin | -79.56% |
| Return on Equity | -95.96% |
Analyst Ratings as of 07/21/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |